+34 679 490 537info@nanbiosis.com

Nanbiosis

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone
Ciber bbn

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dra. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC
IQAC CSIC
Order request

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

Active projects

TitleFundin: OrganismCall: Funding source Role
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Partner
PICCOLO-732111Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision supportEuropean Commission-H2020H2020-ICT-2016-1Partner
0624_2IQBIONEURO_6_EPromotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseasesEuropean Union Interreg : European Territorial Co-operationPOCTEP Interreg España-PortugalPartner

Other projects

RefTitleFunding OrganismUnit Role
SAF2015-67476-RImmunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS)Ministerio de Economía y CompetitividadParticipant
PIE1400061Molecular links between diabetes and neurodegenerative diseasesISCIIIOberver
2014SGR1484Consolidated Research GroupGeneralitat de CatalunyaParticipant
FP7-614168Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP)European CommissionOberver
CI16-00031 Caixa ImpulseA new approach for the detection of Pseudomonas aeruginosaCaixaBankParticipant
MSCA-ITN2015-675412New Diagnostics for Infectious DiseasesEuropean CommissionParticipant
TECCTP15-1-0011Ajuda acreditació Tecnio del grup Nb4DACCIÓ: Generalitat de CatalunyaOthers

Publications

2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

29 Nov

Nb4D group- NANBIOSIS U2 receives the acreditation TECNICO, in the on line event organizes by ACCIO

Las November 27 was held the ACCIO ceremony (on line this year due to the Covid Pandemic restrictions) of disclosure of new TECNIO accreditations. Aurea Rodriguez, Director of Business Innovation at ACCIO has welcomed the attendees to the event. Later, the TECNIO program Coordinator, Marta Peidro, presented the background and rationale for this accreditation for excellence groups in technology transfer in Catalonia. This year there have been five new groups from among all Catalan universities and research organizations, which have obtained the TECNIO accreditation for the first time, making a total of fifty-four groups accredited in 2020. The event continued[...]

13 Nov

Nb4D group – NANBIOSIS Unit 2 CAbS – accredited with the TECNIO seal

The Nb4D group of CIBER-BBN and IQAB-CSIC, coordinator of NANBIOSIS Unit 2 Custom Antibody Service (CAbS), has been accredited with the TECNIO seal. This accreditation is the hallmark TECNIO granted by the Government of Catalonia, through ACCIÓ, to identify the developers and facilitators of differential technologies in Catalonia. TECNIO is the umbrella brand for catalan technology centres and university research groups dedicated to industrial research and technology transfer. ACCIO, CERTIFICATION, QUALITY MANAGEMENT SYSTEM[...]

02 Nov

Prof. Pilar Marco, in the program “Meridiano Turing” of RTVE explains the COVID-19 tests.

The last edition of the program “Meridiano Turing” of RTVE interviews Maria Pilar Marco Head of CIBER-BBN and IQAC-CSIC group Nb4D and NANBIOSIS-ICTS Unit 2 Custom Antibody Service (CAbS), Cesar Fernández (Head of the Chemical Transducers Group at IMB-CNM, CSIC) and María Cruz Minguillón (EGAR group at IDAEA) Pilar Marco y César Fernández, the authors of the block of the CSIC’s report entitled “Containment and diagnosis“, explain wich is the best way to diagnose COVID and how reliable are the tests in this moment. What is needed is to detect an infection -says Pilar Marco- is viral material and w[...]

02 Oct

New updated version of the CSIC report on COVID-19

The report by Spanish Higher Council for Scientific Research (CSIC) summarizng the most relevant scientific results on the Covid-19 pandemic.  “A global vision of the Covid-19 pandemic: What we know and what we are investigating from CSIC”, has just published its version number 4. This report is structured in five blocks: prevention, disease, containment and diagnosis, treatment and vaccines, and global impact. The containment and diagnosis block describes how the virus is transmitted in the air indoors and the analysis of wastewater as a system for early detection of SARS-CoV-2 is explained. In addition, the importance of diagnosis in t[...]

21 Sep

NANBIOSIS Expertise in the IQAC-CSIC Symposium dedicated to the fight against Covid-19 Pandemic

The 4th Annual IQAC Symposium will take place on September 23, 2020. This year will be dedicated to the research projects on COVID-19 that are being carried out in the IQAC-CSIC. It will be a dissemination day aiming to inform the general public about some of the lines of research that are currently being developed in the fight against the COVID-19 pandemic. The event will be live streamed in Facebook: facebook.com/iqac.csic.es/ Three of the speakers, members of CIBER-BBN NANBIOSIS units at IQAC-CSIC, will explain their work. Pilar Marco and Roger Galve (NANBIOSIS U2 Custom Antibody Service (CAbS) will talk about[...]

12 Aug

NANBIOSIS U2 expands its capabilities with a two new equpipments

The U2 of NANBIOSIS, Custom Antibody Service (CAbS) has expanded its capabilities with two new equipment items an Automated microdispensing system for microarray technology and a Nitrogen Tank Cryomemo. The Automated microdispensing system for microarray technology is a sciFLEXARRAYER S3 is an automated piezo driven, non-contact dispensing system of ultra-low volumes specifically designed as an economical entry unit for academia and R&D labs. It consists of XYZ-stages with spindle drives, a piezo dispensing unit and precision equipment for liquid handling. The system handles volumes from 50 picoliters up to several microliters. The S3 is suitable for the production  DNA, protein,[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

01 Jun

New methods to detect Coronavirus: interactive webinar on the diagnosis of COVID-19

CSIC has orgnized an interactive webinar on new COVID-19 detection systems that brings together biotechnologist Luis Blanco, nanotechnologists Laura Lechuga and Pilar Marco, and physicist Javier Tamayo . Researchers from the Higher Council for Scientific Research (CSIC) will answer citizens’ questions about the diagnostic methods of the SARS-CoV-2 coronavirus, which causes Covid-19, in a webinar or interactive debate that will be broadcast on Wednesday, June 3, at 8:15 p.m., on the CSIC YouTube channel. The meeting will feature the participation of biotechnologist Luis Blanco, the physicist Javier Tamayo and the nanotechnologists Laura Lechuga, Scientific Director of NANBIOSIS unti 4 Biodeposition[...]

U2-Custom Antibody Service (CAbS)
Read More

U25. NMR: Biomedical Applications I

Ciber bbn

U25. NMR: Biomedical Applications I

  • Scientific Director: Prof. Carles Arús Carles.Arus@uab.es
  • Scientific Coordinator: Ana Paula Candiota AnaPaula.Candiota@uab.cat
  • Entities: Servicio de Resonancia Magnética Nuclear (SeRMN) & Institut de Biotecnología i Biomedicina (IBB) & Universidad Autónoma de Barcelona (UAB)
  • Address: Facultad de Ciencias, Edificio C, 08193, Cerdanyola del Vallés, Barcelona, Spain
  • Phone: +34 935 814 126
  • Web: GABRMN-UAB seRMN-UAB

UAB

Order request

Description

The platform is divided between the Servei de Ressonància Magnètica Nuclear (Nuclear Magnetic Resonance Facility) (SeRMN) (http://sermn.uab.cat/) and the Institut de Biotecnologia i Biomedicina (IBB) for bioinformatics applications of the UAB . This platform is coordinated by Prof. Carles Arús, PI of the Nuclear Magnetic Resonance Biomedical Applications Group (GABRMN) (http://gabrmn.uab.es/), with a recognized research track record in the use of NMR as a tool for biomedical applications, and more especifically to identify biomarkers of different pathologies. The main objective of the Platform of Biomedical Applications of Nuclear Magnetic Resonance at the Universitat Autònoma de Barcelona (UAB) is the acquisition, processing and/or interpretation of Nuclear Magnetic Resonance data.

The platform is equipped with 10 spectrometers operating at magnetic fields between 5.8 and 14.1 Teslas (T), including a MRI scanner, Bruker BioSpec, equipped with a 7T horizontal magnet for preclinical trials.

The unit also hosts a computational platform at the IBB, with a total storage capacity of 12TB, which is accessible through the UAB network. The computational platform also hosts two multicentre databases (INTERPRET and eTUMOUR), with NMR and clinical data for more than 1000 human brain tumour patients.

The uniqueness in this case lies in access, in the same location, equipment for NMR studies in vivo, ex vivo and in vitro, molecular imaging accessories by using polarization as well as fixed metabolomic patterns. This configuration allows to validate results of molecular imaging in vivo with other in vitro facilities.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Publications

2016

  • Delgado-Goni T., Ortega-Martorell S., Ciezka M., Olier I., Candiota A.P., Julia-Sape M. et al. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine. 2016;:-.
  • Cordon-Barris L., Pascual-Guiral S., Yang S., Gimenez-Llort L., Lope-Piedrafita S., Niemeyer C. et al. Mutation of the 3-phosphoinositide-dependent protein kinase 1 (PDK1) substrate-docking site in the developing brain causes microcephaly with abnormal brain morphogenesis independently of akt, leading to impaired cognition and disruptive behaviors. Molecular and Cellular Biology. 2016;36(23):2967-2982.
  • Ferrer-Font L., Alcaraz E., Plana M., Candiota A.P., Itarte E., Arus C.. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. Pathology and Oncology Research. 2016;:-.
  • Ciezka M., Acosta M., Herranz C., Canals J.M., Pumarola M., Candiota A.P. et al. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation. Journal of Neuro-Oncology. 2016;:1-10.

News U25

10 Sep

Robust Conditional Independence maps of single-voxel Magnetic Resonance Spectra to elucidate associations between brain tumours and metabolites

Scientists of CIBER-BBN, Ana Paula Candiota and Margarida Juliá managing Nanbiosis ICTS U25 NMR: Biomedical Applications I have participated in the research carried out by Liverpool John Moores University and University of Valencia to elucidate associations between brain tumours and metabolites, published by the journal Plos One. The aim of the paper is two-fold. First, to show that structure finding with the PC algorithm can be inherently unstable and requires further operational constraints in order to consistently obtain models that are faithful to the data. The authors propose a methodology to stabilise the structure finding process, minimising both false positiv[...]

18 Aug

The ATTRACT Online Conference open for registration

The on line Conference ATTRACT – Igniting the Deep Tech Revolution will take pace on 22-23 Sep 2020. The ATTRACT Online Conference website is now live! Please register before 28 August at https://attract-eu-conference.cern.b2match.io/ The ATTRACT Conference offers multiple opportunities to understand the dynamics and contribute to the emergence of a strong European deep tech ecosystem for detection and imaging technologies. The ATTRACT Project is an EC funded initiative led by a consortium of leading European research infrastructures and universities. CIBERBBN and Nanbiosis are involved in MAGRes : Multiparametric MR approaches for non-invasive glioblastoma therapy response follow-up, one of the 170 projects using sensing and imaging technologyto[...]

17 Aug

The Autonomous University of Barcelona, in the elite of the 300 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world and the first of the Spanish universities. This indicator organizes up to 20,000 university centers worldwide, based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The Autonomous University of Barcelona houses two of NANBIOSIS Units: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Paolo Saccardo, offer an “tailored”[...]

04 Jun

Open call for contribution to the Special Issue by MDPI in IJMS about “In Vivo Biomarkers for Immunotherapy Efficacy in Brain Tumours”

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25 NMR: Biomedical Applications I Unit (from CIBER-BBN and Autonomous University of Barcelona), is the Guest Editor of a special issue launched by MDPI in the International Journal of Molecular Sciences (IF 4.183). This special issue is about “In Vivo Biomarkers for Immunotherapy Efficacy in Brain Tumours” Contributions with papers or reviews to this issue, can be fowarded to the Guest Editor (AnaPaula.Candiota@uab.cat) with a tentative title and/or abstract. Final deadline for submission: 31/10/2020[...]

10 Oct

Preclinical brain tumour therapy response assessment with MRSI approaches: Oral presentation awarded to Ana Paula Candiota

NANBIOSIS U25 scientific coordinator, Ana Paula Candiota, has recently presented a scientific work about preclinical brain tumour therapy response assessment with MRSI approaches in the 36th annual meeting of ESMRMB held in Rotterdam, Netherlands, October 3-5. Work was entitled  “Oscillatory pattern of response in MRSI-based Glioblastoma therapy follow-up: an immune system biomarker?” and was awarded an oral presentation in the scientific session of Animal Models: Brain & others Article of refrence: L. Villamañan, P. Calero, S. Wu, N. Arias-Ramos, M. Pumarola, S. Ortega-Martorell, M. Julià-Sapé, C. Arús, A.P. Candiota. Oscillatory pattern of response in MRSI-based Glioblastoma therapy follow-up: an immune system[...]

17 Aug

The Autonomous University of Barcelona, in the elite of the 300 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide, based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The Autonomous University of Barcelona houses two of NANBIOSIS Units: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Paolo Saccardo, offer an “tailored” service for the design, production and purification[...]

20 May

Multiparametric MR approaches for non-invasive glioblastoma therapy response follow-up (MAGRes)

Ana Paula Candiota, Scientific coordinator of U25 of NANBIOSIS, is the IP of the granted project Multiparametric MR approaches for non-invasive Glioblastoma therapy response follow-up (MAGRes), selected for funding in the ATTRACT call https://attract-eu.com/the-project/ The kick-off meeting for is taking place at CERN, Switzerland, days 20-21th May with talks of all selected projects. Unit 25 will have a relevant role in the development of MAGRes. MRI/MRSI from preclinical brain tumors will be acquired at NANBIOSIS U25, NMR: Biomedical Applications I[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

U25-NMR Biomedical Applications I
Read More

U26. NMR: Biomedical Applications II

Ciber bbn

U26. NMR: Biomedical Applications II

  • Scientific Director: Prof. Ramon Martinez Máñez  rmaez@qim.upv.es
  • Scientific Coordinator: Dr. Salvador Gil salvador.gil@uv.es
  • Entities: Universitat de Valencia (UV)
  • Address: C/Dr. Moliner, 50, Edificico Investigación, 1º Pl., 46100, Valencia, Spain
  • Phone: +34 963877343
  • Tel Prof. Martínez: +34 963877343 ; Tel Dr. Gil : +34 963543135
  • Web: UV

UV

Order request

Description

Located in the Faculty of Medicine of the University of Valencia (UV) has a laboratory with a NMR (14T) for acquiring unique metabolic profiles of biofluids, cell lines and tissues. This Unit is coordinated by Dr. Ramón Martínez Máñez, PI of the Applied Molecular Chemistry Group of the Universidad Politécnica de Valencia, together with Dr. Salvador Gil, Director of the Central Service for Experimental Research (SCSIE).

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
MAT2015-64139-C4-1-R INTELLIGENT NANOMATERIALS, PROBES AND DEVICES FOR THE INTEGRATED DEVELOPMENT OF NEW TOOLS APPLIED TO THE BIOMEDICAL FIELD MINISTERIO DE ECONOMIA INDUSTRIA Y COMPETITIVIDAD Participant
MAT2015-64139-C4-C-R CHROMOGENIC AND FLUOROGENIC CHEMOSENSES FOR THE DETECTION OF NEUROTRANSMITTERS MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD Participant
PROMETEOII/2014/047 New approaches for the design of controlled release materials and the detection of dangerous compounds Generalitat Valenciana Participant
AP2012-1478 HELP CONV FPU 2012 - DE LA TORRE PAREDES, CRISTINA Ministerio de Educacion, cultura y deporte Participant
MAT2012-38429-C04-01 Development of functionalized materials with nanoscopic doors for controlled release applications and sensors for the detection of ammonium nitrate, sulfuric acid and CO Ministerio de Economia y Competitividad Participant
UPV-FE-16-A1 CONSTITUTION OF A SMART DRUG DISCOVERY PLATFORM Participant
UPV-FE-15-A2 Development of nanomaterials and sensors for early and non-invasive diagnosis and prognosis UNIVERSIDAD POLITECNICA DE VALENCIA Participant
AP2013-06017 HELP CONTRACT FPU 2013-SANCHEZ CABEZAS MInisterio de Educacion, Cultura y Deporte Participant

Publications

2016

  • Rosales A.M., Aznar E., Coll C., Garcia Mendoza R.A., Lorena Urbano Bojorge A., Gonzalez N.F. et al. Study of the dependency of the specific power absorption rate on several characteristics of the excitation magnetic signal when irradiating a SPION-containing ferrofluid. Journal of Magnetics. 2016;21(3):460-467.

News U26

26 Nov

The Nanomedicine Revolution

Yesterday, November, 25 took place, within the the program of the Ateneo of the EINA (School of Engineering and Architecture of Aragón), the online conference on “The Revolution of Nanomedicine” by Ramón Martínez Máñez. The Conference chair, Jesús Martínez de la Fuente, Principal Investigator of the BIONANOSURF group of CIBER-BBN and the Institute of Nanoscience and Materials of Aragón, introduced the guest, Ramón Martínez Máñez, Scientific Director of CIBER-BBN, highlighting “his creativity in the use of his systems and how he combines them with different diagnostic release systems, combining organic chemistry, surface chemistry, applications in biotechnology and giving way to[...]

13 Nov

How to delay vision loss in hereditary retinal dystrophies? Looking for the most effective and economical pharmacological nanotherapy

Researchers from the CIBER-BBN and NANBIOSIS are participating in a new project that aims to achieve the most effective, specific and economical pharmacological nanotherapy that allows delaying the death of retinal cells and subsequent loss of vision in hereditary retinal dystrophy. retinitis pigmentosa, regardless of the genetic defect causing the disease. In this project, coordinated by the researcher Regina Rodrigo, the ONCE and the Prince Felipe Research Center (CIPF) of Valencia collaborate, together with researchers from the CIBER of Rare Diseases (CIBERER) and the Manises Hospital in Valencia. On behalf of the CIBER-BBN, the scientific director, Ramón Martínez Máñez, together[...]

08 Oct

New test trials to diagnose Covid 19: Ramon Martinez, Scientific Director of CIBER-BBN is interviewed by Spanish Television

Ramón Martinez, Scientific Director of CIBER-BBN and NANBIOSIS unit 26 NMR: Biomedical Applications II is interviewed by Spanish Television about the research he is coordinating at the Polytechnic University of Valencia to develop new tests as an alternative to PCR. Dr. Elena Aznar CIBER researcher at IQMA-IDM-UPV group explains how work these test that allow to diagnose quickly, easily, reliably and cheaply if a person is or has been infected by the SARS-COV-2 virus. Ramón Martínez Máñez, leader of the project, reports on the point where the investigation is, as well as the difference of these tests with PCR or[...]

29 Sep

COVID-19 detection system: a fast, cheap and easy to use alternative to PCR.

PCR (acronym in English for “Polymeric Chain Reaction”), is a type of diagnostic test for the detection of infectious diseases. The PCR diagnosis of COVID-19 used since the outbreak of the pandemic offers a high level of specificity and sensitivity but presents a certain degree of complexity, requiring specialized personnel and is expensive. Researchers from Polytechnic University of Valencia (UPV), the Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), the La Fe Health Research Institute (IIS La Fe) and the consortium Centro de Investigación Biomédica en Red de Bioengineering, Biomateriales y Nanomedicina (CIBER-BBN) has[...]

22 Sep

II Conference on Nanotoxicity. “Dosis sola facit venenum”

NANBIOSIS has participated in the organization of the on-line Conference on Nanotoxicity in collaboration with, CIBER-BBN, Nanomed Spain and Materplat, to debate about the efect of nanotoxicity of nanoparticles and nanotechnologies in health. The session has been started by Ramon Martinez Mañez, Scientific Director of CIBER-BBN and NANBIOSIS U26 NMR: Biomedical Applications II. Isabel Rodriguez (GAIKER Technlogy Center) has taking about tools for risk management of nanomatials differentiating between tools and strategies and explaining their experience in studies carried out. Luis Rojo del Olmo investigador del Grupo de Biomateriales del Instituto de Ciencia y Tecnología de Polímeros del CSIC y del CIBER-BBN) has spoken[...]

12 Jun

Seminar on Molecular probes and gated materials in biomedical applications by Ramón Martínez, now in youtube

Last June 8, 2020,  Ramón Martínez Máñez, Scientific Director of CIBER-BBN and NANBIOSIS U26, gave an on line seminar, hosted by Jaume Veciana and Anna Roig will from ICMAB-CSIC on Molecular probes and gated materials in biomedical applications and communication between nanoparticles. If you missed the seminar, you can see it now on YouTube: More information at the ICMAB website.[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

27 May

Peptide‐Capped Mesoporous Nanoparticles: Toward a more Efficient Internalization of Alendronate.

Osteoporosis is an illness which appears when the osteoblast/osteoclast activities are unbalanced taking place bone resorption (caused by osteoclasts) in higher extension than bone formation (induced by osteoblasts). Alendronate is one of the most used drugs for osteoporosis treatment despite its scarce bioavailability. In an attempt to improve it, gated mesoporous silica nanoparticles, for the controlled release of alendronate, have been synthesized and characterized. These hybrid nanoparticles include labelled alendronate inside the porous, those porous are capped with a peptide designed to be selectively cleaved by cathepsin K enzyme (overexpressed in osteoclasts). Two CIBER-BBN units of the ICTS NANBIOSIS wer[...]

U26-NMR Biomedical Applications II
Read More

U28. NanoImaging Unit

Bionand

U28. NanoImaging Unit

 

    • Scientific Director: Prof. José Becerra Ratia jbecerra@bionand.es
    • Head NanoImaging Unit: Dr. Mª Luisa García Martín mlgarcia@bionand.es
    • Entities: Andalusian Centre for Nanomedicine and Biotechnology (BIONAND)
    • Address: C/Severo Ochoa 35, 29590, Málaga, Spain
    • Phone: +34 952 367 600
    • Web: BIONAND

 

 

 

 

 

 

 

Junta de Anadalucía Universidad de Málaga

Order request

Description

 

The Nanoimaging Unit is located in Malaga at the Andalusian Centre for Nanomedicina and Biotechnology (BIONAND), and it has been conceived and optimized to provide very diverse and integrated technological support for nanotechnology-based biomedical research, offering advance services to internal and external users. This facility is coordinated by Dr. Mª Luisa García Martín, who has a wide expertise in the field of Magnetic Resonance Imaging and Spectroscopy applied to biomedical research.

The Unit brings together a wide range of cutting-edge technologies, and it is divided into four departments, each with a dedicated specialist:

– Small Animal Multimodal Imaging: Small animal (pre-clinical) imaging is a vital tool in biomedical research that allows biological processes and potential medicines to be studied in animal models using non-invasive methods. This department offers some of the most relevant pre-clinical imaging modalities, namely, MRI, in vivo Bioluminiscence and Fluorescence Imaging, and micro-CT. These techniques are essential for preclinical evaluation and characterization of new diagnostic and therapeutic agents. The combined use of these technologies and new highly specific imaging probes are the basis of molecular imaging.

– Magnetic Resonance (NMR): it is equipped with two High resolution NMR Spectrometers: a 400MHz NMR spectrometer for routine experiments and a higher field, 600 MHz, spectrometer dedicated to high resolution magic angle spinning (HR-MAS) NMR and in vitro studies that are very demanding in terms of sensitivity. It also has a TD-NMR analyzer for relaxivity measurements at clinical field (1.44 T).

– Electron Microscopy: It offers access to transmission electron microscopy (TEM), Cryo-TEM and Electron Tomography, high resolution scanning electron microscopy (SEM) and environmental SEM. A special emphasis has been made on high-end sample preparation techniques through cryo-inmobilization. All the equipments have been configured to provide its best on biological and nanomedicine applications. TEM, SEM and sample preparation facilities and services are offered to provide structural characterizations at the micro and nano scales. Biological and medical applications are the main objective of these equipments but are not limited to them. Any other scientific and engineering field can take advantage of them due to its versatility for public and private research, quality control, failure analysis, etc.

– Advanced Fluorescence: It hosts an excellent range of facilities capable of supporting high quality biomedical research. These applications can range from the initial characterization of the fluorescent properties of novel nano-compounds to the evaluation of their medical applications using tissue culture and animal models.In addition, the range of possible applications goes far beyond nanomedicine to include the characterization of patient tissues, preclinical studies using rodent models, small scale drug screening and studies using model organisms such as Zebrafish or Drosophila Melanogaster. The service is operated in close collaboration with the other advanced facilities of the Nanoimaging Unit, and the other units of Bionand, to ensure that researchers can easily combine fluorescence-based techniques with other complementary approaches such as Electron microscopy or Nuclear Magnetic Resonance.

Moreover, the location of the NanoImaging Unit allows it to be linked to other complementary Units available at BIONAND, such as the Cell Culture Unit (containment level 1 and 2), the Chemical Unit (it offers a wide range of equipment and techniques in which materials and their interaction with biological samples can be characterized), the Animal House (rat, mouse and zebra fish accomodation), and the Histology Unit (it also offers Cutting/grinding based histological sectioning for hard tissues or other materials unsuitable to be sectioned by routine methods)

Services

 

 

 

In addition to the services within the NanoImaging Unit, the following specialised services are offered:

– Cutting/grinding based histological sectioning (Onsite&Remote) OUTSTANDING: This technique is recommended for obtaining histological samples from hard tissues or other materials unsuitable to be sectioned by routine methods, e.g. undecalcified bone tissue, metallic or ceramic implants, or samples that combine hard and soft components. With the EXAKT system, 10-15 μm slices can be made without disrupting the interface between areas of different hardnesses. Applications: Processing and fixation of fresh samples, Dehydration, plastic infiltration and polymerization, Cutting of blocks to obtain surfaces of interest, Block grinding, Histological staining.

– Animal Housing (Onsite&Remote): The BIONAND Animal Facility Service is a research support service that aims to house experimental animals: zebra fish, rats and mice, and provide the facilities, materials, equipment and expertise needed to conduct pre-clinical trials based on the technologies and products developed in Centre from both research groups and companies

U28. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
T96 BIOMEDICAL SIGNAL INTERPRETATION & COMPUTATIONAL SIMULATION DGA Participant
UZCUD2016-TEC-03 Optimization of a submersible device for the monitoring of the photoplestimográfica signal CUD Participant
DPI2016-75458-R MULTI-SCALE PHYSIOLOGY-DRIVEN COMPUTATIONAL TOOLS TO ASSIST IN THE ASSESSMENT AND MANAGEMENT OF CARDIAC DYSFUNCTIONS MINECO Participant
TIN2013-41998-R THE AUTONOMOUS NERVOUS SYSTEM AS A MODULATOR OF CARDIAC FUNCTION: INTEGRAL RESEARCH THROUGH SIGNAL PROCESSING AND COMPUTATIONAL MODELING MINECO Participant

Publications

2016

 

  • Laguna P., Martinez Cortes J.P., Pueyo E.. Techniques for Ventricular Repolarization Instability Assessment from the ECG. Proceedings of the IEEE. 2016;104(2):392-415.
  • Pueyo E., Dangerfield C.E., Britton O.J., Virag L., Kistamas K., Szentandrassy N. et al. Experimentally-based computational investigation into beat-to-beat variability in ventricular repolarization and its response to ionic current inhibition. PLoS ONE. 2016;11(3):-.
  • Romero D., Martinez J.P., Laguna P., Pueyo E.. Ischemia detection from morphological QRS angle changes. Physiological Measurement. 2016;37(7):1004-1023.
  • Vicente J., Laguna P., Bartra A., Bailon R.. Drowsiness detection using heart rate variability. Medical and Biological Engineering and Computing. 2016;:1-11.
  • Alcaine A., De Groot N.M.S., Laguna P., Martinez J.P., Houben R.P.M.. Spatiotemporal model-based estimation of high-density atrial fibrillation activation maps. Digital Signal Processing: A Review Journal. 2016;54:64-74.
  • Bolea J., Pueyo E., Orini M., Bailon R.. Influence of heart rate in non-linear HRV indices as a sampling rate effect evaluated on supine and standing. Frontiers in Physiology. 2016;7(NOV):-.
  • Ortigosa N., Rodriguez-Lopez M., Bailon R., Sarvari S.I., Sitges M., Gratacos E. et al. Heart morphology differences induced by intrauterine growth restriction and preterm birth measured on the ECG at preadolescent age. Journal of Electrocardiology. 2016;:-.
  • Hernando A., Lazaro J., Gil E., Arza A., Garzon J.M., Lopez-Anton R. et al. Inclusion of Respiratory Frequency Information in Heart Rate Variability Analysis for Stress Assessment. IEEE Journal of Biomedical and Health Informatics. 2016;20(4):1016-1025.

U28. NanoImaging Unit
Read More

U29. Oligonucleotide Synthesis Platform (OSP)

U2 CAbS-hybridoma clone
Ciber bbn

U29. Oligonucleotide Synthesis Platform (OSP)

  • Scientific Director: Prof. Ramon Eritja: recgma@cid.csic.es
  • Scientific Coordinator: Dr. Anna Aviñó: aaagma@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 145
  • Web: IQAC- CSIC
IQAC CSIC
Order request

Description

This unit is coordinated by the Nucleic Acids Chemistry Group at the Institute for Advanced Chemistry of Catalonia (IQAC), Spanish National Research Council (CSIC) and has the equipment needed for the production of oligonucleotides at low scale (mg to mg), purification, characterization and post-synthesis modification. The service counts with laboratories for synthesis and modification of oligonucleotides including DNA/RNA synthesizer, analytical and semi-preparative HPLC equipment for the purification and characterization of oligonucleotides. The service will focus in providing expert opinion to researchers as well as the production of tailored oligonucleotides. Routine synthesis of oligonucleotides used as primers will not be produced as there is a large number of commercial sources that provide a quick and low price service. The oligonucleotide synthesis platform will focus in providing modified oligonucleotides (ONs) that are difficult to obtain from commercial sources. These include microgram to milligram amounts of DNA and RNA derivatives carrying several modifications as well as oligonucleotide conjugates carrying lipids, membrane-receptors ligands, carbohydrates and peptides designed for therapeutic or diagnostic purposes. The facility benefits from the wide experience of Prof. Ramon Eritja that has more than 30 years expertise in the development of modified oligonucleotides.

Active projects

RefTitleFundin OrganismRole
CTQ2017-84415-R STUDY OF ADN STRUCTURES WITH BIOMEDICAL POTENTIALMINECOCoordinator

Other projects

RefTitleFundin OrganismRole
SBPLY/17/180501/000376Development and validation of new intelligent administration systems of RNAs in the injured spinal cord: application in a neuroprotective therapy based on miR-138Junta de Castilla-La Mancha Participant
BIO2017-92113-EXP New tailored microRNA-based antifungal agents for crop protectionMINECO - Explora-Participant
CA17103CA17103 Delivery of antisense RNA therapeutics (DARTER) C.C.E.E. COST Action Participant
AC18/00046Monitoring of Acquired Brain Injury and recovery of biomarkers by the combined label-free NanoSensing of multiple circulating molecules (ABISens).Euronanomed-III (ERA-Net cofund action on Nanomedicine)Participant
CSIC-COV19-041Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV) Consejo Superior de Investigaciones Científicas (CSIC)Participant
Prometeo/2020/081Use of microRNA modulators as experimental therapies in type 1 myotonic dystrophy Generalitat Valenciana Participant

Publications

2019

“Synthesis of oligonucleotides carrying nucleic acid derivatives of biomedical and structural interest” Eritja, R., Aviñó, A., Fàbrega, C., Alagia, A., Jorge, A.F., Grijalvo, S. In “Enzymatic and chemical synthesis of nucleic acid derivatives” (Fernández Lucas and Camarasa Eds) Willey-VCH Verlag, Weinheim (Germany), pp 237-258, (2019).

Cationic niosomes as non-viral vehicles for nucleic acids. Challenges and opportunities in gene delivery. Grijalvo, S., Puras, G., Zárate, J., Sainz-Ramos, M., AL Qtaish, N., López, T., Mashal, M., Attia, N., Díaz Díaz, D., Pons, R., Fernández, E., Pedraz, J.L., Eritja, R.  Pharmaceutics, 11(2), 50 (2019).

“Parallel clamps and polypurine hairpins (PPRH) for gene silencing and triplex-affinity capture: design, synthesis and use” Aviñó, A., Eritja, R., Cuidad, C., Noe, V. Current Protocols on Nucleic Acid Chemistry, e78 (2019).

“Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy” Aviñó, A., Unzueta, U., Cespedes, M.V., Casanova, I., Vázquez, E., Villaverde, A., Mangues, R., Eritja, R. ChemistryOpen, 8, 382-387 (2019).

“The small interfering RNAs (siRNAs) in cancer therapy: nano-based approach” Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C.D., Memari, F., Miri, S.R., Rad, M.R., Marmari, V. Int. J. Nanomedicine, 14, 3111-3128 (2019).

“The origins and the biological consequences of the Pur/Pyr DNA•RNA asymmetry” Terrazas, M., Genna, V., Portella, G., Villegas, N., Sánchez, D., Arnan, C., Pulido-Quetglas, C., Johnson, E., Guigó, R., Brun-Heath, I., Aviñó, A., Eritja, R., Orozco, M. Chem., 5, 1619-1631 (2019).

“On the race for more stretchable and tough hydrogels” Grijalvo, S., Eritja, R., Díaz Díaz, D. Gels, 5, 24 (2019).

“Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes” Mashal, M., Attia, N., Martínez-Navarrete, G., Soto-Sánchez, C., Fernández, E., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Control. Rel., 304, 181-190 (2019).

“Study of conformational transitions of i-motif DNA using time-resolved fluorescence and multivariate analysis methods” Benabou, S., Ruckebusch, C., Sliwa, M., Aviñó, A., Eritja, R., Gargallo, R., de Juan, A.  Nucleic Acids Res., 47, 6590-6605 (2019).

“Expanding the limits of amide-triazole isosteric substitution in bisamide-based physical gels” Tautz, M., Torras, J., Grijalvo, S., Eritja, R., Saldías, C., Alemán, C., Díaz Díaz D. RSC Adv., 9, 20841-20851 (2019).

“Aptamer-peptide conjugates as a new strategy to modulate human α-thrombin binding affinity” Aviñó, A., Jorge, A.F., Huertas, C.S., Cova, T.F.G.G., Pais, A., Lechuga, L.M., Eritja, R., Fàbrega, C. Biochim. Biophys. Acta (General subjects), 1863, 1610-1630 (2019).

“Cationic niosome-based hBMP7 gene transfection of neuronal precursor NT2 cells to reduce the migration of glioma cells in vitro” Attia, N., Mashal, M., Grijalvo, S., Eritja, R., Puras, G., Pedraz, J.L. J. Drug Delivery Science Technol., 53, 101219 (2019).

“Stabilization of c-KIT G-quadruplex DNA structures by the RNA polymerase I inhibitors BMH-21 and BA-41” Mazzini, S., Gargallo, R., Musso, L., De Santis, F., Aviñó, A., Scaglioni, L., Eritja, R., Di Nicola, M., Zunino, F., Amatulli, A., Dallavalle, S. Int. J. Mol. Sci., 20, 4927 (2019).

“Alginate hydrogels as scaffolds and delivery systems to repair the damaged spinal cord” Grijalvo, S., Nieto-Díaz, M., Maza, R.M., Eritja, R., Díaz Díaz, D. Biotech J., 14, e1900275 (2019).

“A pH-dependent bolt involving cytosine bases located in the lateral loops of antiparallel G-quadruplex structures within the SMARCA4 gene promotor” Benabou S., Mazzini, S., Aviñó, A., Eritja, R. Gargallo, R. Sci. Rep., 9, 15807 (2019).

2018

Selective depletion of metastatic stem cells as therapy for human colorectal cancer. Céspedes, M.V., Unzueta, U., Aviñó, A., Gallardo, A., Álamo, P., Sala, R., Sánchez-Sardi, A., Casanova, I., Mangues, M.A., Lopez-Pousa, A., Eritja, R., Villaverde, A., Vázquez, E., Mangues, R. EMBO Mol. Med., 10, e8772 (2018).

DNA-based nanoscaffolds as vehicles for 5-fluoro-2’-deoxyuridine oligomers in colorectal cancer therapy. Jorge, A.F., Aviñó, A., Pais, A.A.C.C., Eritja, R., Fàbrega, C. Nanoscale, 10, 7238-7249 (2018).

Exploring PAZ/3’-overhang interaction to improve siRNA specificity. A combined experimental and modeling study. Alagia, A., Jorge, A.F., Aviño, A., Cova, T.F.G.G., Crehuet, R., Grijalvo, S., Alberto Pais, A.A.C.C., Eritja, R. Chem. Sci., 9, 2074-2086 (2018).

DNA origami-driven lithography for patterning on gold surfaces with sub-10 nanometer resolution. Gállego, I., Manning, B., Prades, J.D., Mir, M., Samitier, J., Eritja, R. Adv. Mat., 29, 1603233 (2017).

Glucose-nucleobase pseudo base pairs as a new biomolecular interaction in a DNA context. Vengut-Climent, E., Gómez-Pinto, I., Lucas, R., Peñalver, P., Aviñó, A., Fonseca-Guerra, C, Bickelhaupt, F.M.., Eritja, R., González, C., Morales, J.C. Angew. Chem. Int. Ed. Engl., 55, 8643-8647 (2016).

News U29

22 Nov

Closer to understand the regulation of SMARCA4 expression

Researchers of NANBIOSIS U29 Oligonucleotide Synthesis Platform (OSP) from CIBERBBN at @IQAC_CSIC, led by Prof. Ramón Eritja, are the authors of an article published by Int J Biol Macromol. 2020, entitled “Influence of pH and a porphyrin ligand on the stability of a G-quadruplex structure within a duplex segment near the promoter region of theSMARCA4 gene”. Prof Eritja hightlighs the contribution to this work by Dr. Raimundo Gargallo from the University of Barcelona. The manuscript described the structural analysis of the promoter region of the SMARCA4 gene involved in ovarian cancer. This promoter region has an exceptionally long G-rich sequence.[...]

05 Nov

How to take advantage of the body’s natural processes to create innovative therapies?

During the month of October took place the Spanish Society of atherosclerosis (SEA 2020) Virtual meetings, promoted by Novartis. Prof. Ramon Eritja, Scientific Director of NANBIOSIS U29 Oligonucleotide Synthesis Platform (OSP) (from CIBERBBN at IQAC_CSIC), was the guess speaker in the session “Innovation and future therapeutic strategies in dyslipidemia” giving the conference entitled “How to take advantage of the body’s natural processes to create innovative therapies“, in the telematic congress of the Spanish society of atherosclerosis (SEA 2020) in the session “Innovation and future therapeutic strategies in dyslipidemia”.Dr. Ramon Eritja, explained the mechanism of action of some new drugs based[...]

08 Jun

NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking

The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

09 Apr

NANBIOSIS U2, U3 & U29 participate in the POC4CoV project to develop diagnostic technologies for SARS-COV-2

The Spanish Higher Council for Scientific Research (CSIC) will finance the project Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV), whose objective is to have effective diagnostic technologies for Covid-19. The Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) and the Institute of Materials Science of Aragon (ICMA) participate in it. The POC4CoV project aims to develop Point-of-Care (POC) devices for the in vitro diagnosis of SARS-COV-2 infection quickly and reliably, thanks to the use of multiplexed systems and the use of particular biomolecular probes. To do this, POC technological platforms will b[...]

07 Feb

Ethylcellulose nanoparticles as new “in vitro” tool for cell transfection

Researchers of NANBIOSIS U12 Nanostructured liquid characterization unit and U29 Oligonucleotide Synthesis Platform (OSP) of CIBER-BBN at IQAC-CSIC have obtained successfully ethylcellulose nanoparticles with positive zeta potential formed from nano-emulsion complexation with an antisense oligonucleotide which result very promising complexes for “in vitro” cell transfection. A new non-viral gene delivery vector has been developed, based on ethylcellulose, an easily available and low cost carbohydrate polymer, “generally recognized as safe” by the FDA. Although ethylcellulose is nonionic, positively charged nanoparticle dispersions have been obtained using nano-emulsion templates in cationic:non-ionic surfactant-based systems. The nanoparticles have been successfully complexed with negatively charged phosphorothioate antisens[...]

26 Apr

Nanbiosis_U10_Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids
Cationic nioplexes in supramolecular hydrogels as hybrid materials to deliver nucleic acids

Jose Luis Pedraz, Scientific Director of Unit 10 of NANBIOSIS Drug Formulation unit and Ramon Eritja Scientific Director of Unit U29 of NANBIOSIS Oligonucleotide Synthesis Platform (OSP) (CIBER-BBN) have participated in the entrapment of cationic nioplexes in supramolecular hydrogels and the use of these materials for transfecting cells. This work is focused on entrapping cationic nioplexes within supramolecular hydrogels based on N-protected phenylalanine. To modulate the supramolecular hydrogel diffusion properties, hydrogels were easily tuned with ĸ-carrageenan (≤ 1%). These materials were fully characterized using rheology. The niosomal liberation in solution through hydrogels was monitored by fluorescence and this release was[...]

U29. Oligonucleotide Synthesis Platform
Read More